MARK SCHOENEBAUM is a Senior Managing Director, heads ISI’s Health Care Research Team and is ISI’s Biotechnology & Pharmaceuticals-Major Analyst. He has been ranked Institutional Investor #1 Biotechnology analyst for the past 8 years. In 2012, his first year competing in the category, Mark was also ranked by Institutional Investor as a top 3 Pharmaceuticals/Major analyst. In addition, Mark has been highly ranked in the Greenwich Associates survey for several years.

Prior to joining ISI in 2010, Mark spent 2 years at Deutsche Bank as a Managing Director and Senior Biotechnology Analyst. Prior to that, Mark held a similar position at Bear Stearns.

Mark graduated from Indiana University with highest distinction in 1996 with a BA and received an MD from the Johns Hopkins University School of Medicine in 2000.